Associates

Endeavour Capital is fortunate to have Associates with wide experience in the technology sector to assist the company to maximize opportunities using combined experience and global networks.

Dr Bernard Cummings
Dr. Bernard Cummings graduated from the University of Otago Medical School in 1991, where he was awarded his Bachelors of Medicine and Surgery (MBChB).

Bernard furthered his education at the Royal Australian College of Surgeons, Australia, and at the London Business School where he was awarded a Sloan Fellowship in Management (Sloan MBA), specializing in New Venture Development in the Life Sciences Sector.

In 2006, Dr. Cummings founded Montreal Logic Ltd. UK – a company providing investors with commercial due diligence on early-stage ventures for medical device and biopharmaceutical markets.

His recent roles include consultation to both Orteg Bioengineering in London – a privately held venture-backed company with CE Mark approval for a synthetic meniscal implant, and Abingworth Management Ltd, London - a company managing $1.25 billion for life science investment.

Dr. Cummings has been associated with Endeavour Capital since 2003.

George F. Steinfels, PhD, MBA
Venture Partner

Dr. Steinfels is a twenty-five year veteran of the medical technology industry, with expertise in product development and commercialization. He has held positions of CSO, COO, CBO, and CEO in large and small, private and public medical technology companies. His diversified career that included executive positions in biopharmaceutical companies and the contract research industry resulted in achievements that ranged from discovery and clinical development of drugs with novel mechanisms to launch of several blockbuster pharmaceuticals.

More recently, Dr. Steinfels founded BoneGrafix Inc. BoneGrafix is a privately held medical device and biomaterials company engaged in the development and commercialization of innovative synthetic bone products that promote rapid healing and remodeling of bone tissue. The Company’s technology is expected to produce cost-effective products which combine the regenerative and remodeling features of autografts with the best properties of allografts and synthetic bone.

Dr. Steinfels has written and published extensively and speaks at business conferences on various topics in the medical technology industry. Dr. Steinfels received a BA in Biology from The Johns Hopkins, an MS and PhD in Pharmacology from the University of Maryland, Postdoctoral studies at Princeton University, and an MBA from The Wharton School of Business of the University of Pennsylvania.

Dr Aaron Small
Dr. Aaron Small graduated with a PhD in chemistry from Victoria University of Wellington in 2008, where he specialised in the addition of functionality to natural fibres through the use of nanotechnology.

Aaron also works as a Research Fellow at Victoria University, where he is involved in the scale-up and commercialization of a novel technology. He is active in the social media space, where he has recently started a blog (www.thescientistnz.blogspot.com) on science and technology startup issues in New Zealand.

Aaron’s long term career ambition is to work at the interface between business and science, creating successful high growth companies based on sound science and technology.

News and Blog
For the latest articles and posts
click here >>

For the latest information about Endeavour Capital's investment portfolio click here >>

People
Read more about our
Management Team >>
Advisory Board >>

Head office contact details Endeavour Capital
Level Five Wakefield House
90 The Terrace
Wellington
New Zealand
Phone +64 4 499 5140

For further contact details, click here >>